SportsTop StoryTop StoryLatest News
WADA Allows Ozempic, Mounjaro Use Under 2027 Anti-Doping Rules
Sentiment: NeutralHigh Priority
What Happened?
The World Anti-Doping Agency (WADA) has decided to allow athletes to use weight-loss drugs Ozempic and Mounjaro under its 2027 anti-doping rules. These drugs will remain on the monitoring program rather than being banned.
Key points
- WADA's 2027 anti-doping list will take effect on January 1, 2027.
- Ozempic and Mounjaro are classified as GLP-1 receptor agonists.
- WADA cautioned athletes against unsupervised use due to potential health risks.
- The 2027 list allows vaginal administration of glucocorticoids.
- Cannabidiol (CBD) remains permitted, while psychoactive cannabis compounds are still banned.
Key insights
- The decision may influence how athletes approach weight management.
- Athletes could face health risks if using these drugs without supervision.
- The ongoing monitoring of these substances indicates WADA's commitment to athlete safety.
Why it matters
This decision allows athletes to manage weight without violating anti-doping regulations.
Source
Times of India
